Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
T-cell Lymphoma
Interventions
DRUG

BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)

All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02424045 - Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma | Biotech Hunter | Biotech Hunter